Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Expressing GI.1 VP1 Administered to Healthy Adult Volunteers
Conditions
Interventions
VXA-G1.1-NN
Locations
1
United States
AltaSciences LA
Cypress, California, United States
Start Date
January 24, 2022
Primary Completion Date
February 1, 2022
Completion Date
February 24, 2022
Last Updated
June 21, 2024
NCT06944717
NCT05916326
NCT07254728
NCT04875676
NCT06211621
NCT04941261
Lead Sponsor
Vaxart
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions